The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide

British Journal of Pharmacology

Volumn 161, Issue 5, 2010, Pages 1044-1058

  Roger, Séverine ^a   Badier Commander, Cécile ^a   Paysant, Jérôme ^a   Cordi, Alex ^a   Verbeuren, Tony J ^a   Félétou, Michel ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Aggregation; BAY 41 2272; Nitric oxide; Prostacyclin; Soluble guanylyl cyclase

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (N,N DIETHYLAMINO)DIAZENOLATE 2 OXIDE SODIUM; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ADENOSINE DIPHOSPHATE; BERAPROST; CYCLIC AMP; CYCLIC GMP; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HYDROXOCOBALAMIN; N(G) NITROARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; SODIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; QUALITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CYCLIC AMP; CYCLIC GMP; DRUG INTERACTIONS; DRUG SYNERGISM; EPOPROSTENOL; GUANYLATE CYCLASE; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDINES; RATS; RATS, INBRED WKY; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 77958562133     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00943.x     Document Type: Article

References (49)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Anfossi G, Russo I, Massucco P, Mattiello L, Balbo A, Cavalot F et al. (2001). Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content. Thromb Res 102: 319-330.
3. Bawankule DU, Sathishkumar K, Sardar KK, Chanda D, Krishna AV, Prakash VR et al. (2005). BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3, 4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump. J Pharmacol Exp Ther 314: 207-213.
4. Bhardwaj R, Page CP, May GR, Moore PK (1988). Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Eur J Pharmacol 157: 83-91.
5. Dangel O, Mergia E, Karlisch K, Groneberg D, Koesling D, Friebe A (2010). NO-sensitive guanylyl cyclase is the only NO receptor mediating platelet inhibition. J Thromb Haemost 8: 1343-1352.
6. Dickinson NT, Jang EK, Haslam RJ (1997). Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 323: 371-377.
7. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch J-P (2006). NO-independent stimulators and activators of soluble guanylyl cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768.
8. Feijge MA, Ansink K, Vanschoonbeek K, Heemskerk JW (2004). Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem Pharmacol 67: 1559-1567.
9. Furchgott RF (1988). Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM (ed.). Mechanism of Vasodilatation. Raven Press: New York, pp. 401-414.
10. Furchgott RF, Zawadzki JV (1980). The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376.
11. Galle J, Zabel U, Hübner U, Hatzelmann A, Wagner B, Wanner C et al. (1999). Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127: 195-203.
12. Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, Müller-Esterl W et al. (2008). NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost 6: 1376-1384.
13. Garthwaite J (2010). New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications. Mol Cell Biol 334: 221-232.
14. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
15. Gomez E, Schwendemann C, Roger S, Simonet S, Paysant J, Courchay C et al. (2008). Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats. Am J Physiol Heart Circ Physiol 295: H2198-H2211.
16. Gordge MP, Hothersall JS, Noronha-Dutra AA (1998). Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione. Br J Pharmacol 124: 141-148.
17. Hobbs AJ, Moncada S (2003). Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. Vascul Pharmacol 40: 149-154.
18. Homer KL, Wanstall JC (2002). Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate. Br J Pharmacol 137: 1071-1081.
19. Ignarro LJ (1991). Heme-dependent activation of guanylate cyclase by nitric oxide: a novel signal transduction mechanism. Blood Vessels 28: 67-73.
20. Ignarro LJ, Byrns RE, Wood KS (1988). Biochemical and pharmacological properties of EDRF and its similarity to nitric oxide radical. In: Vanhoutte PM (ed.). Mechanism of Vasodilatation. Raven Press: New York, pp. 427-435.
21. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM (1994). YC-1, a novel activator of platelet guanylate cyclase. Blood 84: 4226-4233.
22. Lidbury PS, Antunes E, De Nucci G, Vane JR (1989). Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation. Br J Pharmacol 98: 1275-1280.
23. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S et al. (2000). Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52: 375-414.
24. Maurice DH, Haslam RJ (1990). Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37: 671-681.
25. Mo E, Amin H, Bianco IH, Garthwaite J (2004). Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway. J Biol Chem 18: 26149-26158.
26. Moncada S, Palmer RJM, Higgs EA (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
27. Mullershausen F, Russwurm M, Friebe A, Koesling D (2004). Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109: 1711-1713.
28. Naseem KM, Riba R (2008). Unresolved roles of platelet nitric oxide synthase. J Thromb Haemost 6: 10-19.
29. Negrescu EV, Grünberg B, Kratzer MA, Lorenz R, Siess W (1995). Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. Cardiovasc Drugs Ther 9: 619-629.
30. Radomski MW, Palmer RMJ, Moncada S (1987). The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92: 639-646.
31. Rapoport RM, Murad F (1983). Agonist induced endothelium-dependent relaxation in rat thoracic aorta may be mediated though cyclic GMP. Circ Res 52: 352-357.
32. Reep BR, Lapetina EG (1996). Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost. Biochem Biophys Res Commun 219: 1-5.
33. Rochelle LG, Morana SJ, Kruszyna H, Russell MA, Wilcox DE, Smith RP (1995). Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin. J Pharmacol Exp Ther 275: 48-52.
34. Roy B, Mo E, Vernon J, Garthwaite J (2008a). Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol 153: 1495-1504.
35. Roy B, Halvey EJ, Garthwaite J (2008b). An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase. J Biol Chem 283: 18841-18851.
36. Salvemini D, Radziszewski W, Korbut R, Vane J (1990). The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol 101: 991-995.
37. Schmidt HH, Schmidt PM, Stasch J-P (2009). NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 191: 309-339.
38. Sim AK, McCraw AP, Cleland ME, Nishio S, Umetsu T (1985). Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittelforschung 35: 1816-1818.
39. Smyth EM, FitzGerald GA (2002). Human prostacyclin receptor. Vitam Horm 65: 149-165.
40. Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL (2000). Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 279: 412-419.
41. Stasch J-P, Hobbs AJ (2009). NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191: 277-308.
42. Stasch J-P, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A et al. (2001). NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215.
43. Stasch J-P, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arun Kumar HS, Meurer S et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2261.
44. Teixeira CE, Priviero FB, Todd J Jr, Webb RC (2006a). Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms. Hypertension 47: 596-602.
45. Teixeira CE, Priviero FB, Webb RC (2006b). Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3, 4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole. J Pharmacol Exp Ther 317: 258-266.
46. Tymvios C, Moore C, Jones S, Solomon A, Sanz-Rosa D, Emerson M (2009). Platelet aggregation responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric oxide synthase. Br J Pharmacol 158: 1735-1742.
47. Walter U, Eigenthaler M, Geiger J, Reinhard M (1993). Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. Adv Exp Med Biol 344: 237-249.
48. Wanstall JC, Homer KL, Doggrell SA (2005). Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol 3: 41-53.
49. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM (1995). YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116: 1973-1978.